Crinetics upgraded to buy by Jefferies, atumelnant potential cited

Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company’s drug atumelnant in the treatment of congenital adrenal hyperplasia, or CAH.

The investment bank said